Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 20;217(6):916–925. doi: 10.1093/infdis/jix644

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

PMC Copyright notice

Figure 6. — Sustained adeno-associated virus 6.2FF (AAV6.2FF)–mediated monoclonal antibody (mAb) expression protects mice from mouse-adapted Ebola virus (MA-EBOV) challenge 5 months after a single intramuscular injection. C57BL/6 mice received an intramuscular injection of 2 × 10¹¹ vector genomes of single AAV6.2FF-mAbs (n = 4 per group) or a cocktail of 2 × 10¹¹ vector genomes of AAV6.2FF-2G4 and 2 × 10¹¹ vector genomes of AAV6.2FF-5D2 (n = 4 per group) for a total dose of 4 × 10¹¹ vector genomes. AAV vectors were administered 140 days prior to intraperitoneal challenge with 1000 times the lethal dose (50%) of MA-EBOV. A, Kaplan-Meyer survival plots of AAV6.2FF-2G4, AAV6.2FF-5D2, and AAV6.2FF-2G4/AAV6.2FF-5D2 cocktail (A) and averaged mouse group weights (B).